Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: cancer radiotherapeutics - Algeta

Drug Profile

Research programme: cancer radiotherapeutics - Algeta

Alternative Names: 227Th conjugates; FGFR2-targeted thorium-227 conjugate; HER2-targeted thorium-227 conjugate; Targeted thorium conjugates - Algeta; TH-1 programme; thorium-227 conjugates; TTC - Algeta

Latest Information Update: 28 Apr 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Algeta
  • Developer Algeta; Norwegian Radium Hospital
  • Class Antibodies; Drug conjugates; Monoclonal antibodies; Peptides; Proteins; Radioisotopes; Radiopharmaceuticals
  • Mechanism of Action Fibroblast growth factor receptor antagonists; Glutamate carboxypeptidase II inhibitors; Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 28 Apr 2019 No recent reports of development identified for preclinical development in Cancer in Norway (Parenteral, Injection)
  • 22 Mar 2017 Preclinical development is ongoing in Norway
  • 17 Apr 2014 Lumiphore receives phase II SBIR grant from the US National Science Foundation for the development of cancer radiotherapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top